Lung cancer, as the most prevalent cancer type, is responsible for 11.6% of all cancer cases and 18.4% of all cancer-related mortality. 1 Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for approximately 85% of all lung cancer cases. 2 Currently, common treatments, including surgical resection, chemotherapy, radiotherapy, and targeted therapy, are proposed to patients depending on the tumor stage as well as other critical concerns, such as cardiac and pulmonary functions. 2 For early-stage
patients with NSCLC without surgical contraindications, surgical resection is considered first-line treatment; however, the majority of patients with NSCLC are diagnosed with intermediate to advancedstage disease at hospital admission and have a poor prognosis mainly due to regional recurrence or distant metastases. 3 Thus, it is essential to identify candidate prognostic biomarkers and potential therapeutic targets that could improve the clinical outcomes in patients with NSCLC.
Forkhead box Q1 (FOXQ1), as a member of the forkhead box protein family, has many physiological functions, such as serving as a transcription factor, regulating tumor cell differentiation, promoting epithelial differentiation, and activating T cells and autoimmunity. [4] [5] [6] Recent studies have shown that FOXQ1 is upregulated in several cancers, including breast cancer, colorectal cancer, and hepatocellular carcinoma, and promotes cell proliferation, invasion, and migration in several cancer pathologies. [7] [8] [9] FOXQ1 is also associated with advanced clinicopathological features as well as an unfavorable prognosis in patients with pancreatic cancer, breast cancer, and colorectal cancer. 7, 9, 10 Furthermore, cellular experiments have revealed that FOXQ1 knockdown activates the expression of epithelial markers but decreases the expression of several mesenchymal markers in some epithelial-derived cancers; in particular, FOXQ1 regulates epithelial-mesenchymal transition (EMT), and its knockdown decreases the proliferation, migration, and invasion of NSCLC cells. 11, 12 Regarding the association of FOXQ1 with clinical outcomes in NSCLC, only one clinical study has reported an association of FOXQ1 with clinicopathological features as well as prognosis in patients with NSCLC; however, (a) it is a single-center investigation that might bring in selection bias; (b) it is of a relatively small sample size (only 103 patients are enrolled); (c) disease-free survival (DFS) (a key index for assessing prognosis) is not assessed; (d) the cohort included patients with TNM stage IV, which is a highlight confounding factor; and (e) the follow-up duration is relatively short. 13 Therefore, the implication of FOXQ1 in NSCLC is not clear and needs further exploration.
Thus, we conducted this multicenter study with 238 surgical patients with NSCLC (TNM stage I-III) and aimed to investigate FOXQ1 expression in tumor tissue and adjacent tissue and to further explore the correlation of tumor tissue FOXQ1 expression with clinicopathological properties, DFS, and overall survival (OS) in patients with NSCLC.
| MATERIAL S AND ME THODS

| Patients
In the current retrospective study, 238 patients with NSCLC who underwent surgical resection at our hospitals between January 2013 and December 2014 were screened and reviewed. The screening criteria were as follows: (a) confirmed diagnosis of primary NSCLC according to the World Health Organization (WHO) classification, (b) underwent resection without neoadjuvant therapy, (c) tumor and adjacent tissue specimens removed by surgery were preserved and suitable for immunohistochemistry (IHC), and (d) age above 18 years. Patients were excluded if they were complicated with other tumors or if their clinical or follow-up data were incomplete. The Ethics Committee of our hospitals approved the current study, and all patients or their guardians provided written informed consent or verbal agreement with tape recording.
| Clinical data collection and survival assessment
Patients' clinical data were collected by reviewing the medical records, including age, gender, smoking status, drinking status, pathological differentiation, tumor size, lymph node metastasis, TNM stage (according to the Union for International Cancer Control (UICC) system (7th edition)), and carcinoembryonic antigen (CEA) level, were collected by reviewing medical records. After surgery, patients received adjuvant chemotherapy ± radiotherapy, best supportive care, or observation Finally, the sections were stained with diaminobenzidine (DAB) and hematoxylin and then sealed followed by observation under a light microscope (Leica). A semi-quantitative score was applied to assess the expression of FOXQ1 in the specimens based on the average intensity and density of positively stained cells by IHC. 14 The intensity of positively stained cells was scored as follows: 0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (strong staining); the density of positively stained cells was scored as follows: 0 (0%), 1 (<25%), 2 (26 ~ 50%), 3 (51 ~ 75%), and 4 (>75%). The total IHC score was calculated by multiplying the intensity score by the density score. A total IHC score > 3 was defined as high FOXQ1 expression, and a total IHC score ≤ 3 was defined as low FOXQ1 expression. 
| Specimen collection and detection
| IHC assays
| Statistical analysis
| RE SULTS
| Study flow
A total of 471 patients with NSCLC who underwent surgical resection were screened, and 192 were excluded (including 97 patients whose tumor specimens were inaccessible, 56 patients who underwent neoadjuvant treatment, 32 patients with incomplete clinical data and follow-up records, and 7 patients who were concomitant with other tumors) ( Figure 1 ). The remaining 279 patients with NSCLC were eligible, among which 41 were excluded because they (or their guardians (family members)) were incapable of being contacted for informed consent. Finally, 238 patients with NSCLC were reviewed and analyzed in the study.
| Comparison of FOXQ1 expression between tumor tissue and adjacent tissue
FOXQ1 expression in tumor tissue and adjacent tissue was evaluated by IHC assays (Figure 2A , Figure S1 ). The expression levels of FOXQ1 in tumor tissue and adjacent tissue were different (P < .001) ( Figure 2B ). In tumor tissue, the percentages of tumor tissue with high FOXQ1 expression and low FOXQ1 expression were 61.3% and 38.7%, respectively; in adjacent tissue, the percentages of adjacent tissue with high FOXQ1 expression and low FOXQ1 expression were 37.8% and 62.2%, respectively. These data indicate that FOXQ1 was upregulated in NSCLC tumor tissue compared with adjacent tissue.
| Correlation of FOXQ1 expression with the characteristics of patients with NSCLC.
According to the cutoff value of the FOXQ1 IHC score at baseline, all patients were divided into patients with high FOXQ1 expression (IHC score >3) (n = 146) and patients with low FOXQ1 expression (IHC score ≤3) (n = 92) ( Table 1) 
| Correlation of FOXQ1 expression with DFS and OS
DFS was reduced in patients with high FOXQ1 expression compared with patients with low FOXQ1 expression (P = .016) ( Figure 3A ). OS was also decreased in patients with high FOXQ1 expression compared with patients with low FOXQ1 expression (P = .008) ( Figure 3B ).
The data above suggested that high FOXQ1 expression was associated with an unfavorable prognosis in patients with NSCLC. 
TA B L E 1 Correlation of FOXQ1 expression with patients' characteristics
| Factors predicting DFS by Cox's proportional hazards regression model
The 
| Factors predicting OS by Cox's proportional hazards regression model
The univariate Cox's regression model showed that high FOXQ1 expression (HR = 1.573, P = .009), tumor size (>5 cm) (HR = 2.232, P < .001), lymph node metastasis (HR = 2.728, P < .001), and TNM stage III (HR = 2.256, P < .001) were associated with reduced OS in patients with NSCLC (Table 3) 
| Correlation of FOXQ1 with prognosis in the subgroup analysis
In patients receiving chemotherapy, high FOXQ1 expression was numerically associated with worse OS, although the difference was not significant (P = .145) ( Figure S2A ). In patients without chemotherapy, high FOXQ1 expression was associated with worse OS (P = .034) ( Figure S2B ). In patients receiving radiotherapy, high FOXQ1 expression was associated with worse OS (P = .018) ( Figure S2C ). In patients without radiotherapy, there was no association between FOXQ1 and OS (P = .229) ( Figure S2D ). These data indirectly indicate that FOXQ1 had influence on radiotherapy sensitivity and might have potential to affect chemotherapy sensitivity to some extent.
| D ISCUSS I ON
In the present study, we observed that (a) FOXQ1 was upregulated in NSCLC tumor tissue compared with adjacent tissue, and high was an independent risk factor for DFS and OS in patients with NSCLC.
FOXQ1 is a transcription factor, and its gene is located on human chromosome 6p25.3. 4 Numerous studies have shown that FOXQ1 mediates all steps of tumor metastasis from initial EMT to ultimate organotrophic colonization and is implicated in regulating tumor invasion and metastasis by regulating its downstream genes, such as zinc finger E-box binding homeobox (ZEB2), twist-related protein 1 (TWIST1), and sex-determining region Y-box 12 (SOX12). 15, 16 Given the key role of EMT in epithelial-derived cancers, the role of FOXQ1 has recently been investigated in clinical studies that have indicated that FOXQ1 might act as a tumor promoter in several cancers. 7, 10, 17 For example, one previous study exhibits that FOXQ1 mRNA expression is upregulated in both pancreatic cancer cell lines and tumor tissue, and its high expression is associated with a higher degree of tumor differentiation in patients with pancreatic cancer. 10 Another study illustrates that the expression levels of FOXQ1 mRNA and protein are higher in gastric cancer tissue than in noncancerous tissue, and its elevated expression is associated with larger tumor size, a higher histological grade, lymph node involvement, and tumor-node-metastasis stage. 17 11, 13 However, the previous study is a single-center study with relatively small sample size, which might lead to regional selective bias and reduced validation, and it enrolls the patients at TNM stage IV, which may bring in confounding factors and further leads to bias of the results. Therefore, we excluded patients at TNM stage IV in our study. 
O RCI D
Jinming Yu https://orcid.org/0000-0001-5448-9196
